Form 4: Crinetics Pharmaceuticals Officer Exercises Stock Options
SEC Form 4 Filing
Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, exercised stock options on December 16, 2024.
Summary
- On December 16, 2024, Stephen F. Betz, the Chief Scientific Officer of Crinetics Pharmaceuticals, exercised stock options to acquire 2,331 shares of common stock at a price of $1.91 per share.
- This transaction was reported on a Form 4 filing with the SEC.
- Following the transaction, Mr. Betz directly owns 71,358 shares of Crinetics Pharmaceuticals common stock.
- Mr. Betz also holds options for 180,039 shares.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of an insider transaction.
Industry Context
This is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves a small number of shares relative to the total outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 04/16/2018 | 1/48th of the shares subject to the option vested. |
| 12/16/2024 | Stephen F. Betz exercised stock options. |
| 12/18/2024 | Date of signature on the Form 4 filing. |
| 03/16/2028 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.